A phase I and pharmacokinetic (PK) study of the novel mushroom-derived cytotoxin, MGI 114, in combination with irinotecan in patients with advanced cancer.

被引：0
|
作者：
Eckhardt, SG
Kuhn, JG
Britten, CD
Weitman, S
Baker, SD
MacDonald, JR
Newman, A
Smith, S
Von Hoff, DD
Rowinsky, EK
机构：
[1] MGI PHARMA, Minnetonka, MN USA
[2] Canc Therapy & Res Ctr, San Antonio, TX 78229 USA
来源：
CLINICAL CANCER RESEARCH | 1999年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
319
引用
收藏
页码：3793S / 3793S
页数：1
相关论文
共 50 条
  • [21] Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors
    Couteau, C
    Risse, ML
    Ducreux, M
    Lefresne-Soulas, F
    Riva, A
    Lebecq, A
    Ruffié, P
    Rougier, P
    Lokiec, F
    Bruno, R
    Armand, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) : 3545 - 3552
  • [22] Phase I pharmacokinetic (PK) study of daily imatinib in combination with docetaxel for patients with advanced solid tumors.
    Chatta, GS
    Fakih, M
    Ramalingam, S
    Belani, CP
    Ramanathan, RK
    Zamboni, N
    Friedland, D
    Lis, D
    Tutchko, S
    Egorin, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 138S - 138S
  • [23] A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Dy, GK
    Mandrekar, S
    Peethambaram, PP
    Okuno, SH
    Croghan, GC
    Hanson, LJ
    Furth, A
    Adjei, AA
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (06) : 623 - 628
  • [24] A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer
    Grace K. Dy
    Sumithra Mandrekar
    Prema P. Peethambaram
    Scott H. Okuno
    Gary C. Croghan
    Lorelei J. Hanson
    Alfred Furth
    Alex A. Adjei
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 623 - 628
  • [25] A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer
    Rea, DW
    Nortier, JWR
    Huinink, WWT
    Falk, S
    Riche, DJ
    Maughan, T
    Groenewegen, G
    Smit, JM
    Steven, N
    Bakker, JM
    Semiond, D
    Kerr, DJ
    Punt, CJA
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1123 - 1132
  • [26] A phase I and pharmacokinetic (PK) study of the polyamine biosynthesis inhibitor CGP 48664 in patients with advanced cancer
    Siu, LL
    Rowinsky, EK
    Weiss, GR
    Hammond, L
    Kraynak, M
    Moczygemba, J
    Choi, L
    Linnartz, R
    Porter, C
    DeMoor, C
    Von Hoff, DD
    Eckhardt, SG
    ANNALS OF ONCOLOGY, 1998, 9 : 116 - 116
  • [27] A phase I and pharmacokinetic study of declopramide as a single agent and in combination with IV5-FU/leucovorin in patients with advanced cancer.
    Eckardt, JR
    Schmidt, A
    Denes, A
    Needles, B
    ANNALS OF ONCOLOGY, 2000, 11 : 139 - 139
  • [28] Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Nilofer Azad
    Arvind Dasari
    John Arcaroli
    Gretchen E. Taylor
    Daniel A. Laheru
    Michael A. Carducci
    Martine McManus
    Kevin Quackenbush
    John J. Wright
    Manuel Hidalgo
    Luis A. Diaz
    Ross C. Donehower
    Ming Zhao
    Michelle A. Rudek
    Wells A. Messersmith
    Investigational New Drugs, 2013, 31 : 345 - 354
  • [29] Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Azad, Nilofer
    Dasari, Arvind
    Arcaroli, John
    Taylor, Gretchen E.
    Laheru, Daniel A.
    Carducci, Michael A.
    McManus, Martine
    Quackenbush, Kevin
    Wright, John J.
    Hidalgo, Manuel
    Diaz, Luis A., Jr.
    Donehower, Ross C.
    Zhao, Ming
    Rudek, Michelle A.
    Messersmith, Wells A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 345 - 354
  • [30] Phase I study of irinotecan and amrubicin in patients with advanced non-small-cell lung cancer.
    Kiura, K
    Hotta, K
    Takigawa, N
    Bessho, A
    Harita, S
    Umemura, S
    Ogino, A
    Tabata, M
    Ueoka, H
    Tanimoto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 699S - 699S
12345